JP2023539589A5 - - Google Patents
Info
- Publication number
- JP2023539589A5 JP2023539589A5 JP2023513309A JP2023513309A JP2023539589A5 JP 2023539589 A5 JP2023539589 A5 JP 2023539589A5 JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023539589 A5 JP2023539589 A5 JP 2023539589A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- egfr
- pharmaceutical composition
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069748P | 2020-08-25 | 2020-08-25 | |
| US63/069,748 | 2020-08-25 | ||
| PCT/IB2021/057794 WO2022043895A2 (en) | 2020-08-25 | 2021-08-25 | Treatment of non-small lung cancer with egfr mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539589A JP2023539589A (ja) | 2023-09-15 |
| JP2023539589A5 true JP2023539589A5 (https=) | 2024-09-02 |
Family
ID=80352814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513309A Pending JP2023539589A (ja) | 2020-08-25 | 2021-08-25 | Ｅｇｆｒ変異を有する非小細胞肺がんの治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12528869B2 (https=) |
| EP (1) | EP4204455A4 (https=) |
| JP (1) | JP2023539589A (https=) |
| KR (1) | KR20230053686A (https=) |
| CN (1) | CN116194141A (https=) |
| AU (1) | AU2021330539A1 (https=) |
| CA (1) | CA3192922A1 (https=) |
| IL (1) | IL300854A (https=) |
| JO (1) | JOP20230039A1 (https=) |
| MX (1) | MX2023002362A (https=) |
| WO (1) | WO2022043895A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230174677A1 (en) * | 2021-11-16 | 2023-06-08 | Janssen Biotech, Inc. | Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL) |
| WO2024003837A1 (en) * | 2022-06-30 | 2024-01-04 | Janssen Biotech, Inc. | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer |
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| CN116284335A (zh) * | 2023-03-17 | 2023-06-23 | 云南中医药大学 | Egfr基因突变体的检测方法及应用 |
| WO2025158277A1 (en) * | 2024-01-22 | 2025-07-31 | Janssen Biotech, Inc. | Use of amivantamab to treat head and neck cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT3904391T (pt) | 2010-03-10 | 2024-10-14 | Genmab As | Anticorpos monoclonais contra c-met |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| WO2012142535A2 (en) | 2011-04-15 | 2012-10-18 | Esco Corporation | Replaceable wear parts for an earth-working roll |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| US20170275367A1 (en) * | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| KR102771603B1 (ko) | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| WO2020102647A1 (en) | 2018-11-15 | 2020-05-22 | Invenra Inc. | Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| BR112023018278A2 (pt) | 2021-03-09 | 2023-10-31 | Janssen Biotech Inc | Tratamento de cânceres sem mutações de ativação de egfr |
-
2021
- 2021-08-25 CN CN202180052496.5A patent/CN116194141A/zh active Pending
- 2021-08-25 WO PCT/IB2021/057794 patent/WO2022043895A2/en not_active Ceased
- 2021-08-25 MX MX2023002362A patent/MX2023002362A/es unknown
- 2021-08-25 AU AU2021330539A patent/AU2021330539A1/en active Pending
- 2021-08-25 JP JP2023513309A patent/JP2023539589A/ja active Pending
- 2021-08-25 EP EP21860686.1A patent/EP4204455A4/en active Pending
- 2021-08-25 IL IL300854A patent/IL300854A/en unknown
- 2021-08-25 CA CA3192922A patent/CA3192922A1/en active Pending
- 2021-08-25 KR KR1020237009896A patent/KR20230053686A/ko active Pending
- 2021-08-25 US US17/411,158 patent/US12528869B2/en active Active
-
2023
- 2023-02-23 JO JOJO/P/2023/0039A patent/JOP20230039A1/ar unknown
-
2025
- 2025-11-14 US US19/389,439 patent/US20260070993A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539589A5 (https=) | ||
| EP3903828A1 (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
| JP2024153659A5 (https=) | ||
| Khalil et al. | Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer | |
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| CN101998851A (zh) | 吡铂和西妥昔单抗治疗结直肠癌的用途 | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| JP2023513297A5 (https=) | ||
| KR20140023921A (ko) | ＥｒｂＢ 경로 저해제들에 대한 저항성을 극복하는 방법 | |
| MX2013013018A (es) | Metodo para el tratamiento oncologico combinado dirigido a egfr. | |
| EP4464337A1 (en) | Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents | |
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| WO2017205216A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| JP7761490B2 (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| JP2025500784A5 (https=) | ||
| CN104892763A (zh) | 抗体-药物偶联物Pertuzumab-MCC-DM1、其与Trastuzumab的组合物及其应用 | |
| JP2022531980A5 (https=) | ||
| US20240343807A1 (en) | Pharmaceutical composition for treating small cell lung cancer | |
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| CN113766917A (zh) | 用于治疗头颈癌的喹啉衍生物 | |
| JP2024509920A5 (https=) | ||
| WO2019096233A1 (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途 | |
| WO2023072043A1 (zh) | 治疗肿瘤的联用药物 | |
| HK40063551A (en) | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor |